



Co-infection HIV & HCV management in Dept of Infectious Diseases, UHC “Mother Teresa”

**D.SH.M K. Shkurti, Prof Dh. Kraja, D. Nika,
D.SH.M A. Harxhi, D.SH. M N. Como, E. Kolovani**
Infectious Diseases Clinic University Hospital
Center “Mother Theresa”, Tirana, Albania



Epidemiology data

33 million HIV-infected persons worldwide (in 2007) → 4-5 million HIV+HCV

Prisoners in the US HIV+HCV → 65-70%, whereas in general HIV patients → 18-25%

Eastern European countries (Byelorussia, Ukraine) in i/ v drug use (IDU) co-infection HIV+HCV >70%

Central European countries (Belgium, Austria or Germany) the rate of HIV+HCV co-infection is 10-15%

Albania rate of co-infection HIV+HCV is 6% (P.H.I)

From 134 cases HIV+ followed in our clinic, 9 of them are co-infected with HCV (6.7%)



▣ **Objective:**

The author's aim is to contribute coverage and completion of treatment in patients with co-infection HIV + HCV, especially for mobile population

▣ **Material:**

9 cases with coinfection HIV + HCV followed up in our clinic in period of 2000-2008

▣ **Methods**

We analyzed cases according to clinical signs, activity of HCV, activity of HIV infection and management of each case separately




Our ambulatory clinic in Infectious Diseases Dept University Hospital Center “Mother Theresa”, Tirana





Geographic distribution of HIV + cases in Albania (Public Health Institute)


SHPERNDARJA GJEOGRAFIKE E PACIENTEVE HIV/ AIDS



RESULTS

From 9 cases HIV+HCV

- A ► in 5 cases liver enzymes are < 2 fold of normal range
- B ► in 4 cases liver enzymes are > 3-5 fold of normal range



A ► in 5 cases


■ 2 cases ↑ HCV RNA levels:

- First case (Sex Worker) is co-infected HIV+ HCV+ HBV in cirrhotic stage is under treatment with ARV (CD4<200)
- The second case is under treatment with ARV, PEG-INF + Ribavirin

■ 1 case ↓ HCV RNA levels & CD4>350 (follow up)


■ In 2 cases PCR (HCV) is no available and they didn't follow medical treatment

- 1 case (IDU) was under treatment with ARV (CD4 <100)




B ► in 4 cases

- 1 case (emigrant) interrupt our follow up
- 2 cases are under treatment with Peg-INF + Ribavirine and ARV
(↑ HCV & ↑ HIV RNA levels, CD4 < 150)
- 1 case from Rome population has no possibility to find specific treatment for HCV and refused ARV (↑ HCV & ↑ HIV RNA, CD4 200)




RESULTS

From 9 cases HIV+HCV, 3 of them (33%) didn't follow medical treatment (1 case IDU and 1 case emigrant)



RESULTS

From 9 cases HIV+HCV, 5 of them (55%) are under treatment with ARV





CONCLUSIONS

- **From 134 cases, 9 are co-infected HIV+HCV (6.7%)**
- **From 9 cases HIV+HCV, 3 of them (33%) didn't follow medical treatment (1 IDU, 1 emigrant)**
- **From 9 cases HIV+HCV, 5 of them (55%) are under treatment with ARV**
- **From 9 cases HIV+HCV 3 cases (33,3%) are under treatment for both HCV & HIV infections**



RECOMANDATION

- **Improvement of evaluation, providing in time PCR assay in patients co-infected HIV & HCV especially for mobile population.**
- **Providing necessary antiviral treatment for hepatitis in patient co-infected with HIV and hepatitis**



REFERENCES

- Mauss – Berg- Rockstroh- Sarrazin- Wedemeyer. Hepatology a clinical textbook, 2009: 285-294
- Bacon BR. Treatment of patients with Hepatitis C and normal serum aminotransferase levels. Hepatology 2002, 36 (5 Suppl 1): S 179-S184.
- Broers B, Helbling B, Francois A et al. Barriers to interferon –alpha therapy are higher in intra-venousdrug users than in other patients with acute hepatitis C. J. Hepatol 2005; 42(3):323-8
- Comberg M, Huppe D, Wiegand J et al Treatment of chronic Hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3. Z gastroenterol 2003; 41(6):517-22.
- EACS Guidelines, 2007, 45-50, EACS Guidelines 2008, 37-40.
- Guide to HIV, pregnancy and women’s health Jan 2009, 36.